

Reference Number: FOIAH2324/489
From: Commercial
Date: 06 December 2023
Subject: Trust spend on unlicensed medication

Q1 What is the total value of spend by your NHS Trust on unlicensed medication (i.e. Special Order, Drug Tariff Special Order, Part VIID Drug Tariff Special Order) that have a BNF liquid formulation (e.g. liquid, solution, suspension)? Please provide this information on a volume and value basis for the following years (please fill in the tables below).
Note: Value of spend to mean either net ingredient cost or actual cost. Please state which you have used below. Actual cost would be the total cost to NHS commissioners whereas NIC is the cost at list price excluding VAT.

A1

Type	Total spend / cost on liquid unlicensed products procured		
	Apr-20 to Mar 21	Apr-21 to Mar 22	Apr-22 to Mar-23
Special Order	£717,498.85	£930,428.91	£971,743.85
Drug Tariff Special Order	0	0	0
Part VIID Drug Tariff Special Order	0	0	0
Other Special	0	0	0

Type	Total volume of mLs liquid unlicensed products procured		
	Apr-20 to Mar 21	Apr-21 to Mar 22	Apr-22 to Mar 23
Special Order	5420974 mL	6071479 mL	6519064 mL
Drug Tariff Special Order	0	0	0
Part VIID Drug Tariff Special Order	0	0	0
Other Special	0	0	0

Q2 Do you outsource the manufacturing of liquid unlicensed products?

A2 Yes

Q3 If no to question 2 (use of outsourcing providers), what proportion of the products that you manufacture in-house are aseptically compounded rather than terminally sterilised?

A3 Not Applicable as per A2

Q4 If yes to question 3 (use of outsourcing providers), what is the total value of spend by

provider? Please provide this information for the following years (please fill in the tables below).

Note: If more than 10 providers are used, please only detail spend with the top 10.

A4 Information exempt under Section 43 - Due to the potential damage to commercial interests of the current suppliers as release of this information and any other unique pricing likely to be requested for disclosure would allow other competitors a significant competitive advantage and thus harm the commercial interests of our current suppliers.